Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $4.9 million.

  • Coeptis Therapeutics Holdings' Cash & Equivalents rose 33153.36% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 33153.36%. This contributed to the annual value of $532885.0 for FY2024, which is 6372.8% down from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Cash & Equivalents is $4.9 million, which was up 33153.36% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Cash & Equivalents registered a high of $7.4 million during Q3 2022, and its lowest value of $532885.0 during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $2.3 million, with a median of $2.0 million in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 116077.32% in 2022, then tumbled by 8085.03% in 2023.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Cash & Equivalents (Quarter) stood at $2.2 million in 2021, then surged by 73.95% to $3.8 million in 2022, then crashed by 61.25% to $1.5 million in 2023, then tumbled by 63.73% to $532885.0 in 2024, then soared by 821.12% to $4.9 million in 2025.
  • Its Cash & Equivalents was $4.9 million in Q3 2025, compared to $2.0 million in Q2 2025 and $4.3 million in Q1 2025.